Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1987 5
1988 18
1989 31
1990 13
1991 15
1992 14
1993 21
1994 15
1995 26
1996 19
1997 19
1998 20
1999 20
2000 29
2001 22
2002 34
2003 27
2004 37
2005 29
2006 27
2007 32
2008 26
2009 28
2010 27
2011 39
2012 36
2013 52
2014 77
2015 79
2016 85
2017 88
2018 110
2019 113
2020 117
2021 118
Text availability
Article attribute
Article type
Publication date

Search Results

1,336 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Tawbi HA, et al. Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Lancet Oncol. 2017. PMID: 28988646 Free PMC article. Clinical Trial.
We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma. METHODS: In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone …
We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with advanced soft-tissue sarcoma or bone sa
Fibrosarcoma: a review and update.
Folpe AL. Folpe AL. Histopathology. 2014 Jan;64(1):12-25. doi: 10.1111/his.12282. Epub 2013 Nov 22. Histopathology. 2014. PMID: 24266941 Review.
Adult fibrosarcoma, defined by the World Health Organization as a 'malignant neoplasm composed of fibroblasts with variable collagen production and, in classical cases, a "herringbone" architecture', is a very rare soft tissue sarcoma. Once considered the most common adult …
Adult fibrosarcoma, defined by the World Health Organization as a 'malignant neoplasm composed of fibroblasts with variable collagen product …
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, Anderson J, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Weiss AR, et al. Lancet Oncol. 2020 Aug;21(8):1110-1122. doi: 10.1016/S1470-2045(20)30325-9. Epub 2020 Jul 20. Lancet Oncol. 2020. PMID: 32702309 Free PMC article. Clinical Trial.
METHODS: In this joint Children's Oncology Group and NRG Oncology multicentre, randomised, open-label, phase 2 trial, we enrolled eligible adults (aged 18 years) and children (aged between 2 and <18 years) from 57 hospitals in the USA and Canada with unresected, newly d …
METHODS: In this joint Children's Oncology Group and NRG Oncology multicentre, randomised, open-label, phase 2 trial, we enrolled eli …
First-Line Therapy for Metastatic Soft Tissue Sarcoma.
Meyer M, Seetharam M. Meyer M, et al. Curr Treat Options Oncol. 2019 Jan 24;20(1):6. doi: 10.1007/s11864-019-0606-9. Curr Treat Options Oncol. 2019. PMID: 30675651 Review.
Soft tissue sarcomas are rare cancers with an expected incidence of about 14,000 new cases in 2018, and account for less than 1% of all cancers. ...Molecular characterization of sarcoma subtypes will likely improve understanding of these very diverse tumors and impr …
Soft tissue sarcomas are rare cancers with an expected incidence of about 14,000 new cases in 2018, and account for less than 1% of a …
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Gounder M, et al. Lancet Oncol. 2020 Nov;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. Epub 2020 Oct 6. Lancet Oncol. 2020. PMID: 33035459 Clinical Trial.
BACKGROUND: Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. ...INTERPRETATION: Tazemetostat was well tolerated and showed …
BACKGROUND: Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expre …
Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D, Lehman J, Tello T, Chimato N, Hocker T, Kim S, Chang J, Markey J, Yom SS, Ryan W, Mully T, Hodge D, Otley C, Arron ST. Winchester D, et al. J Am Acad Dermatol. 2018 Nov;79(5):853-859. doi: 10.1016/j.jaad.2018.05.022. Epub 2018 May 19. J Am Acad Dermatol. 2018. PMID: 29787841
BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) encompasses rare neoplasms that can arise either in the dermis or in the subfascial soft tissue. ...We propose subcategorization of UPS (into superficial versus deep UPS), which is consistent with the American Joint Co …
BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) encompasses rare neoplasms that can arise either in the dermis or in the subfa …
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H. D'Angelo SP, et al. Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19. Lancet Oncol. 2018. PMID: 29370992 Free PMC article. Clinical Trial.
BACKGROUND: Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. ...INTERPRETATION: Nivolumab alone does not warrant further study in an unselected sarcoma popula …
BACKGROUND: Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targe …
The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma.
Heng M, Gupta A, Chung PW, Healey JH, Vaynrub M, Rose PS, Houdek MT, Lin PP, Bishop AJ, Hornicek FJ, Chen YL, Lozano-Calderon S, Holt GE, Han I, Biau D, Niu X, Bernthal NM, Ferguson PC, Wunder JS; Japanese Musculoskeletal Oncology Group (JMOG); Soft Tissue Osteosarcoma International Collaborative (STOIC). Heng M, et al. Eur J Cancer. 2020 Jan;125:130-141. doi: 10.1016/j.ejca.2019.07.029. Epub 2019 Dec 2. Eur J Cancer. 2020. PMID: 31806415 Free PMC article.
PATIENTS AND METHODS: Retrospective review at 25 international sarcoma centers identified patients 18 years old treated for ESOS from 1971 to 2016. ...
PATIENTS AND METHODS: Retrospective review at 25 international sarcoma centers identified patients 18 years old treated for ESOS from …
SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. Sauter JL, et al. Mod Pathol. 2017 Oct;30(10):1422-1432. doi: 10.1038/modpathol.2017.61. Epub 2017 Jun 23. Mod Pathol. 2017. PMID: 28643792
One showed rare TTF1-positive cells. All were negative for desmin, NUT, and S-100 protein. CD34 was positive in three of five (60%) BRG1-deficient tumors tested. ...SMARCA4-deficient thoracic sarcomas can be identified based on their distinctive high-grade rhabdoid …
One showed rare TTF1-positive cells. All were negative for desmin, NUT, and S-100 protein. CD34 was positive in three of five (60%) B …
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Keung EZ, et al. Clin Cancer Res. 2020 Mar 15;26(6):1258-1266. doi: 10.1158/1078-0432.CCR-19-1824. Epub 2020 Jan 3. Clin Cancer Res. 2020. PMID: 31900276 Free PMC article. Clinical Trial.
PURPOSE: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarco …
PURPOSE: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced s
1,336 results